Duke Cancer Institute ( Site 3027)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Metastatic Urothelial Carcinoma, Urothelial Neoplasms

Studies at this site

• A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) — Running, not enrolling